Comment from EU-PEARL
AnonymousSupportAcademic
Summary: A group of researchers and industry experts (including representatives from Berry Consultants, Novartis, and various universities/pharmaceutical companies) provided technical feedback on the draft guidance. They suggest refining terminology, clarifying randomization and blinding options, and adding specific sections on adaptive features unique to platform trials.
See attached file(s)